INMB
NASDAQINmune Bio Inc.
News · 26 weeks36-80%
2026-03-012026-08-23
Mix2090d
- Other9(45%)
- SEC Filings6(30%)
- Insider3(15%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 10-Q filed by INmune Bio Inc.10-Q - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical ProgressBOCA RATON, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced its financial results for the quarter ended June 30, 2026 and provided a business update. "The second quarter and subsequent weeks were defined by execution across both of our late-stage platforms," said David Moss, Chief Executive Officer of INmune Bio. "For Ebstrocel™, we secured MHRA alignment, PIP approval and commercial-ready manufacturing, materially reducing regulatory and operational risk ahead of our planned UK MAA submission. For XPro™, FDA Fast Track designation and statistically significant
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Receives R&D Rebates of Approximately $4.6 MillionBOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter. The rebates strengthen the Company'
- PRINmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6thManagement to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching the operator. Date: August 6th, 2026 Time: 4:30 PM East
- PRINmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ PlatformGlobal Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced the formation of a Scientific Advisory Board ("SAB") to support the late-stage development of Ebstrocel™ for recessive dystrophic epidermolysis bullosa ("RDEB") and guide the expansion of the Company’s proprietary CORDStrom™ mesenchymal stromal cell ("MSC") platform to target new disease indications. The SAB brings together internationally recogni
- PRINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ PlatformCommercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under its co
- PRINmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical StudyThe study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes. Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of Defense–funded study; entitled: "Inhibition of So
- PRINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAICAdvanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p < 0.01), with larger effects observed in patients selected using the company’s biomarker enrichment strategy. BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of XPro in patients wi
- INSIDERDirector Juda Scott exercised 14,801 shares at a strike of $1.40, increasing direct ownership by 21% to 86,404 units (SEC Form 4)4 - Inmune Bio, Inc. (0001711754) (Issuer)
- INSIDERChief Scientific Officer Lowdell Mark William exercised 7,211 shares at a strike of $1.40, increasing direct ownership by 0.48% to 1,518,017 units (SEC Form 4)4 - Inmune Bio, Inc. (0001711754) (Issuer)
- INSIDERChief Executive Officer Moss David J exercised 9,014 shares at a strike of $1.40, increasing direct ownership by 0.70% to 1,294,883 units (SEC Form 4)4 - Inmune Bio, Inc. (0001711754) (Issuer)
- SECINmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written OpinionSecures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla., July 01, 2026 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its CORDStrom™ platform patent application into the U.S. national phase before the United States Patent and Trademark Office (USPTO), advancing a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Hi
- PRINmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). The approval of the PIP is the first required stage toward a Marketing Authorization Application (MAA) submission in the United Kingdom. This regulatory milestone
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEBMHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit, particularity pain and pruritis, and states the data could support positioning as chronic or intermittent supportive therapy for RDEB BOCA RATON, Fla, June 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing
- SECINmune Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialXPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune's precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program. BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imagin
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- PRINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformBoca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer's disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer's Disease with inflammation (ADi) subgroup, XPro™ showed directionally consistent benefit across cognitive, globa
- SECINmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inmune Bio, Inc. (0001711754) (Filer)
- PRINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseBOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ (pegipanermin), the company's first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease (AD). The designation specifically covers XPro™ for treatment of early Alzheimer's disease encompassing both mild cognitive impairment (MCI) due to AD and mild Alzheimer's disease dementia, which represents a large and growing population. "Receiving Fast Track designation from the FDA is a transformative m
- PRINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointAlliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company developing treatments that harness the patient's innate immune system to fight disease, today announced it has been named a founding member of the American Biotech Innovation Alliance (ABIA). The newly launched national coalition brings together biotechnology leaders with the shared objective of defining a national strategy to sustain and extend U.S. leadership in biotech innovation. As part of the ABIA, INmune Bio will collaborate with other industry leaders to address critical
INMB FAQ
7 questionsWhat does INmune Bio Inc. do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in...Where does INMB stock trade?
INmune Bio Inc. (INMB) is listed on NASDAQ.What sector and industry is INMB in?
INmune Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did INmune Bio Inc. go public?
INmune Bio Inc. (INMB) completed its IPO in 2019.What are analysts saying about INMB?
INmune Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Scotiabank: Sector Underperform with a $60.00 price target on 2025-07-01.What companies are similar to INMB?
Notable peers in the same industry include IBRX (ImmunityBio Inc.), GRPH (Graphite Bio Inc.), PALI (Palisade Bio Inc.), PRVB (Provention Bio Inc.), GOSS (Gossamer Bio Inc.). Compare INMB side-by-side with any of them on Quantisnow.How can I track INMB on Quantisnow?
Quantisnow aggregates INmune Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INMB to receive live email and push alerts on every new disclosure.